• Explore /
  • Poster
  • / A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).

A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).

Abstract Video & Slides Poster

Authors

Ashish Kamat

Ashish M. Kamat

The University of Texas MD Anderson Cancer Center, Houston, TX

Ashish M. Kamat , Yair Lotan , Morgan Roupret , Gary D. Steinberg , Brant A. Inman , Thomas Powles , J. Palou Redorta , Sima P. Porten , Girish S. Kulkarni , Edward M. Uchio , Seema Rao Gorla , Gabriel P. Haas , Yao Yu , Yen Lin Chia , Matthew Birrenkott , Max R. Kates

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT05014139

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4596)

DOI

10.1200/JCO.2023.41.16_suppl.4596

Abstract #

4596

Poster Bd #

88

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: Wei Sun

First Author: Erika P. Hamilton

First Author: Jeffrey L. Wong